In: Prakash YS, editor
The inhibitor treatment group (DHEA + GPNA group) received daily subcutaneous injections of DHEA (600 mg/kg body weight) along with intraperitoneal injections of the inhibitor GPNA (200 mg/kg body weight, Selleck, TX, USA) every other day for 21 consecutive days
Potential GH/IGF-1 pathway effects Because both compounds stimulate GH and IGF-1 signaling, researchers often monitor outcomes related to: Fluid retention Edema Glucose regulation Tissue growth signaling Joint discomfort or soft tissue effects Changes in IGF-1 levels CJC-1295 with DAC produced sustained GH and IGF-1 elevation in clinical studies, with no serious adverse reactions reported in the published trial, though the authors noted cumulative effects after repeated dosing. Why DAC may require extra attention Because DAC extends exposure, it may create a longer period of GH/IGF-1 signaling
For a full breakdown of how this combination works, see our explanation of how CJC-1295 and Ipamorelin work together to optimize growth hormone and improve body composition
ROS homeostasis in stem cell maintenance and differentiation Based on the ROS-sensing capacity of cells, stem cells characterized by high differentiation potential and pluripotency exhibit unique response mechanisms to ROS [267, 268]
